Anavex Life Sciences Corp. (NASDAQ:AVXL) PT Set at $15.00 by Maxim Group

Anavex Life Sciences Corp. (NASDAQ:AVXL) has been given a $15.00 price target by investment analysts at Maxim Group in a note issued to investors on Monday, October 30th. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price target indicates a potential upside of 267.65% from the company’s previous close.

Several other equities research analysts also recently issued reports on the company. Noble Financial reissued a “buy” rating and issued a $15.00 price objective on shares of Anavex Life Sciences Corp. in a research note on Friday, September 29th. ValuEngine downgraded Anavex Life Sciences Corp. from a “hold” rating to a “sell” rating in a research note on Thursday, September 28th. Finally, Zacks Investment Research raised Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a research note on Tuesday, September 26th.

Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) opened at $4.08 on Monday. Anavex Life Sciences Corp. has a one year low of $3.17 and a one year high of $6.64.

COPYRIGHT VIOLATION WARNING: This news story was originally published by BBNS and is owned by of BBNS. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/anavex-life-sciences-corp-avxl-given-a-15-00-price-target-by-maxim-group-analysts-2/1745143.html.

Several institutional investors and hedge funds have recently bought and sold shares of AVXL. Bank of New York Mellon Corp raised its stake in shares of Anavex Life Sciences Corp. by 5.5% during the 1st quarter. Bank of New York Mellon Corp now owns 111,880 shares of the biotechnology company’s stock worth $642,000 after purchasing an additional 5,826 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Anavex Life Sciences Corp. during the 1st quarter worth about $105,000. American International Group Inc. raised its stake in shares of Anavex Life Sciences Corp. by 7.1% during the 1st quarter. American International Group Inc. now owns 20,103 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 1,329 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Anavex Life Sciences Corp. by 13.1% during the 1st quarter. Vanguard Group Inc. now owns 1,485,681 shares of the biotechnology company’s stock worth $8,528,000 after purchasing an additional 171,577 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Anavex Life Sciences Corp. by 16.8% during the 1st quarter. Geode Capital Management LLC now owns 276,974 shares of the biotechnology company’s stock worth $1,589,000 after purchasing an additional 39,934 shares in the last quarter. 24.47% of the stock is owned by institutional investors.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with our FREE daily email newsletter.

 


Latest News

Toronto Blue Jays Launch Internal Investigation on PED Use
Toronto Blue Jays Launch Internal Investigation on PED Use
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player


Leave a Reply

 
© 2006-2017 BBNS.